Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312
Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.
Benzinga2 days agoASND
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273
Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.
Benzinga3 days agoASND
Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen
Passes Minervini Trend Template & High Growth Momentum: Ascendis Pharma (ASND) shows strong uptrend, accelerating growth, and analyst upgrades.
ChartMill3 days agoASND
Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target
Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.
Benzinga3 days agoASND
B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.
Benzinga4 days agoASND
Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330
Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.
Benzinga4 days agoASND
Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.
Benzinga4 days agoASND
BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319
BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.
Benzinga16 days agoASND
TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.
Benzinga21 days agoASND
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290
RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $280 to $290.
Benzinga21 days agoASND
Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.
Benzinga21 days agoASND
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call August 13, 2026 8:00 AM EDTCompany ParticipantsChad Fugure - Vice President of Investor RelationsJan...
SeekingAlpha22 days agoASND
Full Transcript: Ascendis Pharma Q2 2026 Earnings Call
Ascendis Pharma (NASDAQ:ASND) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to
Benzinga22 days agoASND
Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate
Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.78 by 34.62 percent. This is a 212.9 percent increase over losses of $(0.93) per share from
Benzinga22 days agoASND
Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup
Ascendis Pharma (ASND) shows high growth momentum with a technical setup rating of 8, triple-digit sales growth, and strong analyst revisions.
ChartMill24 days agoASND
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 17.21%. Currently, Ascendis Pharma has a market capitalization of
Benzinga24 days agoASND